1. Home
  2. DLNG vs ZNTL Comparison

DLNG vs ZNTL Comparison

Compare DLNG & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dynagas LNG Partners LP

DLNG

Dynagas LNG Partners LP

HOLD

Current Price

$3.92

Market Cap

139.0M

ML Signal

HOLD

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

HOLD

Current Price

$2.38

Market Cap

156.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLNG
ZNTL
Founded
2013
2014
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.0M
156.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
DLNG
ZNTL
Price
$3.92
$2.38
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$6.60
AVG Volume (30 Days)
94.5K
614.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
5.08%
N/A
EPS Growth
N/A
47.87
EPS
N/A
N/A
Revenue
N/A
$67,425,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$0.37
N/A
P/E Ratio
$3.04
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.18
$1.01
52 Week High
$4.27
$3.95

Technical Indicators

Market Signals
Indicator
DLNG
ZNTL
Relative Strength Index (RSI) 50.97 46.91
Support Level $3.46 $1.27
Resistance Level $3.97 $2.69
Average True Range (ATR) 0.14 0.17
MACD 0.00 -0.02
Stochastic Oscillator 41.67 32.29

Price Performance

Historical Comparison
DLNG
ZNTL

About DLNG Dynagas LNG Partners LP

Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and are winterized which enables trade in subzero and ice bound conditions.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: